Company: CDT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010405
Chunk: 5

Company: CDT Equity Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 (721) 
     (97)
  
    Accrued expenses and other liabilities 
     (207) 
     49 
  
    Lease liability 
     (28) 
     - 
  
    Net cash flows used in operating activities 
     (4,329) 
     (2,357)
  
    Cash flows used in investing activities: 

    Purchases if property and equipment 
     (4) 
     - 
  
    Net cash flows used in investing activities 
     (4) 
     - 
  
    Cash flows provided by financing activities: 

    Proceeds from issuance of common shares related to ATM program 
     8,061  
     - 
  
    Repayment of notes payable – related parties 
     (425) 
     - 
  
    Repayment of notes payable 
     (151) 
     - 
  
    Repayment of convertible notes payable - related parties 
     (927) 
     - 
  
    Repayment of convertible notes payable 
     (631) 
     - 
  
    Net cash flows provided by financing activities 
     5,927  
     - 
  
    Net change in cash and cash equivalents before effect of exchange rate changes 
     1,594  
     (2,357)
  
    Effect of exchange rate changes on cash and cash equivalents 
     (18) 
     (27)
  
    Net change in cash 
     1,576  
     (2,384)
  
    Cash and cash equivalents at beginning of period 
     554  
     4,228 
  
    Cash and cash equivalents at end of period 
    $2,130  
    $1,844 

    Non-cash investing and financing activities 

    Right of Use Asset obtained in exchange for Operating Lease Liabilities 
    $-  
    $350 
  
    Issuance of Common Stock Upon Exercise of Conversion Option 
    $4,077  
    $- 

    Supplemental Cash Disclosures 

    Cash paid for interest 
    $170  
    $80 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

4

CONDUIT
PHARMACEUTICALS INC.

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1